The wait is over: Lucentis has arrived in Europe
Retinal specialists have a new therapy in their armoury: on January 24th 2007, the European Commission approved ranibizumab (Lucentis, Novartis) for the treatment of patients with wet age-related macular degeneration (AMD).
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Recent Videos
Related Content
